With reports of Alex Bregman signing a three-year deal with the Red Sox, Thursday is a great day for Boston baseball.

Roche Holding AG’s US unit removed diversity and inclusion targets from its website, the latest in a series of publicly traded companies to bow to US President Donald Trump’s push against equal ...

The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...

Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.

Newleos Therapeutics emerged Thursday with $93.5 million and a bundle of oral small molecules that it licensed from Roche, ...

Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...

Roche's sale of InterMune and Esbriet in the US comes as Boehringer revealed its own follow-up play in the IPF, category, ...

UBS upgraded Roche (RHHBY) to Buy from Neutral with a price target of CHF 338, up from CHF 300. The company offers sustainable growth with ...

A $30,000 scholarship programme will be launched alongside internship opportunities for science graduates as Roche Bermuda ...

Roche has reported a 7% increase in full-year 2024 sales at constant exchange rates (CER), reaching CHF 60.5bn ($66.9bn). The ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

Roche (RHHBY) announced that the Food and Drug Administration has approved a New Drug Application for an Evrysdi tablet for people living with ...